Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRK

Merck & Co Inc

Jun 16 • 09:40AM ET

80.48

Dollar change -1.23
Percentage change -1.51	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD SPY IVV VTV XLV VIG VYM IWF

Scroll to Statements

Index	DJIA, S&P 500	P/E	11.72	EPS (ttm)	6.87	Insider Own	0.07%	Shs Outstand	2.52B	Perf Week	1.45%
Market Cap	202.09B	Forward P/E	8.28	EPS next Y	9.72	Insider Trans	-0.19%	Shs Float	2.51B	Perf Month	7.59%
Income	17.43B	PEG	1.00	EPS next Q	2.06	Inst Own	80.32%	Short Float	1.38%	Perf Quarter	-15.10%
Sales	63.78B	P/S	3.17	EPS this Y	16.40%	Inst Trans	0.63%	Short Ratio	2.14	Perf Half Y	-19.32%
Book/sh	19.21	P/B	4.19	EPS next Y	9.16%	ROA	15.78%	Short Interest	34.56M	Perf Year	-38.19%
Cash/sh	3.72	P/C	21.66	EPS next 5Y	11.66%	ROE	39.31%	52W Range	73.31 - 134.63	Perf YTD	-19.10%
Dividend Est.	3.14 (3.90%)	P/FCF	11.86	EPS past 5Y	12.04%	ROIC	21.31%	52W High	-40.22%	Beta	0.40
Dividend TTM	3.20 (3.98%)	Quick Ratio	1.16	Sales past 5Y	6.55%	Gross Margin	74.68%	52W Low	9.78%	ATR (14)	1.96
Dividend Ex-Date	Jun 16, 2025	Current Ratio	1.41	EPS Y/Y TTM	654.93%	Oper. Margin	34.71%	RSI (14)	54.26	Volatility	1.75% 1.22%
Employees	75000	Debt/Eq	0.72	Sales Y/Y TTM	4.40%	Profit Margin	27.33%	Recom	1.88	Target Price	102.10
Option/Short	Yes / Yes	LT Debt/Eq	0.69	EPS Q/Q	7.20%	Payout	46.32%	Rel Volume	0.56	Prev Close	81.71
Sales Surprise	1.24%	EPS Surprise	4.09%	Sales Q/Q	-1.20%	Earnings	Apr 24 BMO	Avg Volume	16.12M	Price	80.48
SMA20	2.66%	SMA50	1.78%	SMA200	-15.67%	Trades		Volume	676,282	Change	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115

Show Previous Ratings

Jun-15-25 05:47AM	Goldman Sachs Remains a Buy on Merck & Co (MRK), Sets a $99.00 PT (Insider Monkey)
Jun-14-25 08:02AM	These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025 (Motley Fool)
Jun-13-25 07:31PM	RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit (Benzinga)
12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
11:00AM	Citizens Financial, Merck, oil producers: Trending Tickers (Yahoo Finance Video)
09:47AM	Loading…
09:47AM	BMY Focuses on Label Expansion of Drugs: Will This Revive Growth? (Zacks)
07:00AM	Investors should be 'embracing volatility' (Yahoo Finance Video)
06:45AM	FDA Approves KEYTRUDA (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent (Business Wire)
05:31AM	MSD begins Phase III trial of dengue vaccine (Clinical Trials Arena)
Jun-12-25 04:45PM	Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI (atinvicitinib) Tablets for Dogs (Business Wire)
10:21AM	PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds (Zacks)
06:45AM	Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate (Business Wire)
Jun-11-25 05:45PM	Here's Why Merck (MRK) Fell More Than Broader Market (Zacks)
04:51PM	Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials (Insider Monkey)
11:30AM	Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA (Insider Monkey)
10:20AM	Loading…
10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
09:36AM	JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects? (Zacks)
05:41AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
Jun-10-25 08:02PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
05:50PM	Merck (MRK) Rises Higher Than Market: Key Facts (Zacks)
10:50AM	Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants (Zacks)
09:46AM	Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE? (Zacks)
08:18AM	Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. (Barrons.com)
Jun-09-25 03:11PM	U.S. FDA Approves Mercks ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season (Business Wire)
02:15PM	Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials (Benzinga)
12:03PM	Merck antibody drug for RSV approved by FDA (BioPharma Dive)
11:08AM	Merck Pill Lowers Cholesterol Levels. By How Much Is the Critical Point. (Barrons.com)
06:45AM	Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia (Business Wire)
05:05AM	Merck claims study success with PCSK9 cholesterol pill (BioPharma Dive)
Jun-07-25 04:30AM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
04:16PM	Loading…
Jun-06-25 04:16PM	Challenges pharma companies face in push into US manufacturing (Yahoo Finance Video)
09:16AM	BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? (Zacks)
Jun-05-25 11:28AM	RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar (Zacks)
09:19AM	Analyst Says Merck (MRK) is 'Really Cheap' But Warns About Potential 'Bad News' (Insider Monkey)
Jun-04-25 05:45PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know (Zacks)
12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks)
12:03PM	Daiichi Sankyo struck gold with ADC cancer drugs. Its new CEO has to figure out whats next. (BioPharma Dive)
10:18AM	Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? (Zacks)
08:55AM	PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo (TipRanks)
08:50AM	Merck granted review of Halozyme patent claims by PTAB (TipRanks)
06:45AM	Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire)
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
06:30AM	Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up (The Daily Upside)
Jun-02-25 11:46AM	Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results (Zacks)
10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
09:38AM	Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study (Zacks)
09:22AM	Are Options Traders Betting on a Big Move in Merck Stock? (Zacks)
08:46AM	Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race (MarketWatch)
02:45AM	Bristol Myers allies with BioNTech on bispecific cancer drug (BioPharma Dive)
May-31-25 08:00AM	KEYTRUDA (pembrolizumab) Plus Trodelvy (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC) (Business Wire)
May-30-25 12:43PM	ASCO25: MSDs ADC candidate achieves 56.3% ORR in lymphoma trial (Clinical Trials Arena)
11:09AM	Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold? (Zacks)
10:00AM	Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates (Zacks)
09:22AM	Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure (Investor's Business Daily)
08:05AM	Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations (Business Wire)
08:00AM	Mercks Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial (Business Wire)
May-29-25 09:18AM	Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
07:36AM	Moderna suffers a $750 million loss from NIH funding cut (Yahoo Finance)
07:00AM	Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn (Business Wire)
06:21AM	Merck, Daiichi pull approval application for ADC in lung cancer (BioPharma Dive)
May-27-25 01:24PM	Merck Announces Third-Quarter 2025 Dividend (Business Wire)
08:17AM	"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy." (Motley Fool)
May-26-25 11:01AM	MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock? (Zacks)
09:16AM	GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer (Zacks)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily)
08:16AM	Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More (Zacks)
May-22-25 08:46AM	CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success (Zacks)
07:15AM	Moderna Stock Looks Ripe for a Short Squeeze (MarketBeat)
06:45AM	Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference (Business Wire)
May-21-25 11:28AM	Merck & Co., Inc. (MRK): A Bull Case Theory (Insider Monkey)
09:05AM	AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip? (Zacks)
May-20-25 10:22AM	MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug (Zacks)
08:46AM	Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech (Zacks)
May-19-25 09:51AM	The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie (Zacks)
08:29AM	PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now? (Zacks)
07:00AM	IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (Business Wire)
06:20AM	Is Invesco Dow Jones Industrial Average Dividend ETF (DJD) a Strong ETF Right Now? (Zacks)
May-18-25 08:31PM	The Top Corporate Board Directors (The Wall Street Journal)
May-16-25 08:06AM	Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals (Zacks)
06:45AM	Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Societys (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension (Business Wire)
May-15-25 03:26PM	FDA awards cancer drug approvals to AbbVie and MSD (Pharmaceutical Technology)
12:05PM	FDA approves Mercks belzutifan for pheochromocytoma or paraganglioma (TipRanks)
10:46AM	Jefferies not seeing significant impact to Merck, Bristol from draft guidance (TipRanks)
06:45AM	Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers (Business Wire)
06:17AM	The Zacks Analyst Blog Highlights Oracle, IBM, Merck and Earth Science Tech (Zacks)
May-14-25 07:56PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
06:44PM	Top Analyst Reports for Oracle, IBM & Merck (Zacks)
05:15PM	FDA Approves Mercks WELIREG (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) (Business Wire)
03:17PM	FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors (Benzinga)
11:31AM	3 Absurdly Cheap Stocks Trading Near Their 52-Week Lows (Motley Fool)
May-13-25 05:06PM	Is Merck & Co. (MRK) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? (Insider Monkey)
09:22AM	The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen (Zacks)
07:36AM	Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared (Zacks)
06:45AM	Research on Novel Treatment Approaches and Scientific Advances From Mercks Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025 (Business Wire)
06:43AM	Zacks Investment Ideas feature highlights: Alibaba, JD.com, SPDR S&P Biotech ETF, Merck and Microsoft (Zacks)
May-12-25 07:20PM	Trump's drug price order is part request, part threat: Analyst (Yahoo Finance Video) +5.87%
04:56PM	Analyst Report: Merck & Co., Inc. (Morningstar Research)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM
Guindo Chirfi	Chief Marketing Officer	Aug 05 '24	Option Exercise	115.20	36,901	4,250,995	57,782	Aug 06 12:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience